Treatment
CAR-T cells clinical trials
We’re tracking 533 recruiting studies that include CAR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT05211557RecruitingPhase 1/Phase 2
CAR-T therapy for recurrent ovarian cancer with B7H3
This Phase 1/2 study tests a personalized immune-cell treatment (fully human B7H3 CAR-T) for ovarian cancer that has come back or did not respond. It aims to see whether CAR-T can attack tumors that carry a target called B7H3.
Xuzhou, JiangsuAges 18–70 - NCT06144151Recruiting
Pupil check to predict CAR-T brain side effects
This study tests if checking your pupil size with a small light device can predict brain-related side effects from CAR-T cell therapy. It is for patients with certain lymphomas receiving axi-cel CAR-T treatment in the hospital.
Houston, TexasAges 18 years+ - NCT06185751RecruitingPhase 1
Testing CS1 CAR-T for multiple myeloma
This study tests a new cell therapy called CS1 CAR-T, which helps your immune system attack myeloma cells that still grow after several other treatments. It's for people who have already tried at least three different types of therapy.
St Louis, MissouriAges 18 years+ - NCT06218602RecruitingPhase 2
Fecal transplant for lymphoma patients getting CAR T therapy
This trial tests whether giving a fecal transplant (a stool enema from a healthy donor) can improve the response to CAR T-cell therapy in people with B-cell lymphoma. It may help by restoring healthy gut bacteria that are often wiped out by strong antibiotics.
Houston, TexasAges 18 years+ - NCT06522932RecruitingPhase 1
PET imaging study for people getting CAR-T therapy for lymphoma
This trial tests a special PET imaging agent (64Cu-GRIP B) to see if it can help track how well CAR-T therapy is working in people with non-Hodgkin lymphoma. It is for patients who have had at least one prior treatment and are scheduled to receive a standard CD19-targeting CAR-T product.
San Francisco, CaliforniaAges 18 years+ - NCT06680752RecruitingPhase 1/Phase 2
A car-t cell therapy trial for AML or MDS
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
Charlotte, North CarolinaAges 18 years+ - NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60 - NCT06971380RecruitingPhase 2
CAR-T therapy for multiple myeloma and amyloidosis
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
JerusalemAges 18 years+ - NCT07031713RecruitingPhase 1
Testing CT1192 cells for lupus that hasn't responded to treatment
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Wuhan, HubeiAges 18–60 - NCT07036250RecruitingPhase 1/Phase 2
Study of U32 for acute myeloid leukemia
This trial tests a new treatment called U32 for people with acute myeloid leukemia (AML) that has come back or not responded to prior therapy. It aims to see if targeting certain proteins on leukemia cells can help control the disease.
SuzhouAges 2–65 - NCT07051850Recruiting
Quality of life study for relapsed myeloma immunotherapy
This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.
Seocho, SeoulAges 19 years+ - NCT07059169Recruiting
CAR-T cell therapy for severe autoimmune diseases
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07169500RecruitingPhase 1/Phase 2
CAR-T with or without stem cell transplant for young women with myeloma
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–50 - NCT07173166Recruiting
Managing side effects after CAR-T treatment
This study tests if non-drug approaches like lifestyle changes or supportive care can reduce nerve-related side effects in people with blood cancers who are receiving CAR-T therapy. It aims to help patients feel better during treatment.
Valencia, ValenciaAges 18–80 - NCT07350837RecruitingEarly Phase 1
CAR-T therapy for highly sensitized kidney transplant patients
This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.
Wuhan, HubeiAges 18–65 - NCT07377435RecruitingPhase 1
Vaccine after CAR-T therapy for multiple myeloma
This trial tests whether a personalized vaccine (DC/MM fusion) given after standard CAR-T cell therapy can help prevent the cancer from coming back. It is for people with multiple myeloma that has returned or not responded to treatment.
Boston, MassachusettsAges 18 years+ - NCT07403097RecruitingPhase 1
CD19 CAR-T therapy for refractory lupus
This trial tests whether a personalized cell therapy called CD19 CAR-T can help people with hard-to-treat lupus (SLE). The treatment uses your own immune cells that have been modified to attack faulty B cells, which are involved in lupus. It is for patients who have moderate to severe disease despite trying multiple standard treatments.
ChongqingAges 5 years+ - NCT06027853RecruitingPhase 1
NK cell therapy for relapsed or refractory AML patients
This trial tests a natural killer (NK) cell therapy that targets a protein called CLL1 on leukemia cells. It aims to help people whose acute myeloid leukemia (AML) has come back or not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07551362RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Gastric Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
Shenzhen, GuangdongAges 18–75 - NCT06248697RecruitingEarly Phase 1
CAR-T cells targeting MSLN with PD-1/CTLA-4 blockers for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07462650RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced colorectal cancer
This trial tests a new treatment using modified natural killer cells (CAR-NK) that target two specific proteins found on your cancer cells. It is for people with advanced colorectal cancer who have tried standard treatments without success.
Shenzhen, GuangdongAges 18–75 - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT07156045RecruitingEarly Phase 1
Study of donor NK cells targeting PSMA for advanced prostate cancer
This trial tests a new treatment using natural killer cells from a healthy donor that are designed to find and attack prostate cancer cells that have a protein called PSMA. It may help men with advanced prostate cancer that has stopped responding to hormone therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07589517RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Colorectal Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
Shenzhen, GuangdongAges 18–75
Common questions
- Are there clinical trials studying CAR-T cells?
- Yes. Clin2 currently lists 533 recruiting studies that include CAR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CAR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CAR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CAR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.